Similar articles

Abstract: Study of the effect of dissolved oxygen and shear stress on rifamycin B fermentation with A. mediterranei XC 9-25 showed that rifamycin B fermentation with amycolatoposis mediterranei XC 9-25 needs high dissolved oxygen and is not very sensitive to shearing stress. The scale-up of rifamycin B fermentation with A. mediterranei XC 9-25 from a shaking flask to a 15 L fermentor was realized by controlling the dissolved oxygen to above 25% of saturation in the fermentation process, and the potency of rifamycin B fermentation in the 15 L fermentor reached 10 g/L after 6-day batch fermentation. By continuously feeding glucose and ammonia in the fermentation process, the potency of rifamycin B fermentaion in the 15 L fermentor reached 18.67 g/L, which was 86.65% higher than that of batch fermentation. Based on the scale-up principle of constantly aerated agitation power per unit volume, the scale-up of rifamycin B fed-batch fermentation with continuous feed from a 15 L fermentor to a 7 m³ fermentor and further to a 60 m³ fermentor was realized successfully. The potency of rifamycin B fermentation in the 7 m³ fermentor and in the 60 m³ fermentor reached 17.25 g/L and 19.11 g/L, respectively.

[1] Bader, F.G., 1986. Modeling mass transfer and agitator per-formance in multiturbine fermentor. Biotechnol Bioeng, 30:37-51.

[2] Chen, J.M., Xu, L.T., 1991. Analysis of Antibiotic Industry. Chinese Press of Pharmaceutical Science, Beijing, p. 109-111 (in Chinese).

[3] Gao, K.N., 1989. Fermentation Engineering and Equipment. Press of Light Industry, Beijing, p.188-222 (in Chinese).

[4] Ghisalba, O., Nüesch, J., 1981. A genetic approach to the biosynthesis of the rifamycin-chromophore in Nocardia mediterranei. IV Identification of 3-amino-hydroxybenzoic acid as a direct precursor of the seven-carbon amino starter-unit. J Antibiot, 34:67-71.

[5] Jin, Z.H., Lin, J.P., Xu, Z.N., Cen, P.L., 2002. Improvement of industry-applied rifamycin B producing strain, Amycolatopsis mediterranei, by rational screening. J Gen Appl Microbiol, 48:329-334.

[6] Kibby, J.J., McDonald, I.A., Richards, W.R., 1980. 3-Amino-5-hydroxybenzoic acid as a key intermediate in asamycin and maytansinoid biosynthesis. J Chem Soc Chem Commun, 1980:768-769.

[7] Lancini, G., Carvelieri, B., 1997. Rifamycins. In: Strohl, W. R. (Ed.), Biotechnology of Antibiotics, vol. 2. Dekker, New York, p.521-549.

[8] Leblihi, A., Germain, P., Lefebvre, G., 1987. Phosphate repression of cephamycin and clavulanic acid production by Streptomyces clavuligerus. Appl Microbiol Biotechnol, 28:44-51.

[9] Oosterhuis, N.M.G., Kossen, N.W.F., 1983. Dissolved oxygen concentration profiles in a production-scale bioreactor. Biotechnol Bioeng, 26:546-550.

[10] Oppolzer, W., Prelog, V., 1973. On the constitution and cofiguration of rifamycin B, O, S and SV. Helv Chim Acta, 56:2287-2314.

[11] Rinehart, K.L.Jr., Shield, L.S., 1976. Chemistry of the ansamycin antibiotics. Fortschr Chem Org Naturst, 33:231-307.

[12] Sensi, P., Thiemann, J.E., 1967. Production of rifamycins. Prog Ind Microbiol, 6:21-59.

[13] Sensi, P., Margalis, P., Timbal, M.T., 1959. Rifamycin, a new antibiotic: preliminary report. Farmaco Ed Sci, 14:146-147.

[14] Sepkowitz, K.A., Rafalli, J., Riley, L., Kiehn, T.E., Armstrong, D., 1995. Tuberculosis in the AIDS era. Clin Microbiol Revs, 8:180-199.

[15] Shuler, F.L., Kargi, F., 1992. Bioprocess Engineering: Basic Concepts. Prentice-Hall, Englewood Cliffs, NJ.

[16] Ziegler, H., Dunn, I.J., Bourine, J.R., 1980. Oxygen transfer and mycelial growth in a tubular loop fermentor. Biotechnol Bioeng, 22:1613-163.